Our Mission
We are a late stage clinical pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases.
Deep expertise fuels our team’s pursuit of solutions, giving us a unique scientific, clinical, and commercial edge. Our sole clinical product candidate, AD109, aims to revolutionize the treatment of obstructive sleep apnea (OSA) as the potentially first oral therapeutic that treats an underlying cause of OSA.
